Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

Introduction: KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods: In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patien...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Anne-Marie Ruppert, MD, PhD, Michèle Beau-Faller, MD, PhD, Didier Debieuvre, MD, L’Houcine Ouafik, MD, PhD, Virginie Westeel, MD PhD, Isabelle Rouquette, MD, Julien Mazières, MD, PhD, Pierre-Paul Bringuier, MD, Isabelle Monnet, MD, Fabienne Escande, MD, Charles Ricordel, MD, Jean-Philippe Merlio, MD, PDh, Henri Janicot, MD, Antoinette Lemoine, MD, PhD, Pascal Foucher, MD, Michel Poudenx, MD, Franck Morin, MSc, Alexandra Langlais, MSc, Pierre-Jean Souquet, MD, PhD, Fabrice Barlesi, MD, PhD, Marie Wislez, MD, PhD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2020-09-01
Serie:	JTO Clinical and Research Reports
Soggetti:	KRAS mutation Non–small cell lung cancer NSCLC Prognosis
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666364320300576
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!